Nanobiotix (NASDAQ:NBTX) — Market Cap & Net Worth
Market Cap & Net Worth: Nanobiotix (NBTX)
Nanobiotix (NASDAQ:NBTX) has a market capitalization of $1.75 Billion ($1.75 Billion) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6671 globally and #2086 in its home market, demonstrating a -9.92% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nanobiotix's stock price $34.40 by its total outstanding shares 50811344 (50.81 Million). Also see balance sheet size of Nanobiotix for a full breakdown of the balance sheet.
Nanobiotix Market Cap History: 2020 to 2026
Nanobiotix's market capitalization history from 2020 to 2026. Data shows growth from $838.39 Million to $1.75 Billion (13.02% CAGR). Also see Nanobiotix (NBTX) cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Nanobiotix is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.07% | #192 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #750 of 3165 |
Weight: Nanobiotix's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Nanobiotix Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nanobiotix's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check NBTX stock price and chart for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
39.63x
Nanobiotix's market cap is 39.63 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $838.39 Million | $2.33 Million | -$33.59 Million | 360.60x | N/A |
| 2021 | $411.57 Million | $2.65 Million | -$47.00 Million | 155.49x | N/A |
| 2022 | $186.48 Million | $4.78 Million | -$57.04 Million | 39.04x | N/A |
| 2023 | $369.91 Million | $36.21 Million | -$39.70 Million | 10.22x | N/A |
| 2024 | $145.83 Million | $-7.19 Million | -$68.13 Million | -20.28x | N/A |
| 2025 | $1.17 Billion | $29.64 Million | -$23.96 Million | 39.63x | N/A |
Competitor Companies of NBTX by Market Capitalization
Companies near Nanobiotix in the global market cap rankings as of September 17, 2026. Review Nanobiotix tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Nanobiotix by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Nanobiotix Historical Marketcap From 2020 to 2026
Between 2020 and today, Nanobiotix's market cap moved from $838.39 Million to $ 1.75 Billion, with a yearly change of 13.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.75 Billion | +48.79% |
| 2025 | $1.17 Billion | +705.57% |
| 2024 | $145.83 Million | -60.58% |
| 2023 | $369.91 Million | +98.37% |
| 2022 | $186.48 Million | -54.69% |
| 2021 | $411.57 Million | -50.91% |
| 2020 | $838.39 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Nanobiotix was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.75 Billion USD |
| MoneyControl | $1.75 Billion USD |
| MarketWatch | $1.75 Billion USD |
| marketcap.company | $1.75 Billion USD |
| Reuters | $1.75 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Nanobiotix
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small … Read more